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Abstract
Psychosomatics as a medical perspective and discipline
focuses on the interaction of physical and mental health in
the specific life situation of a patient, taking into account the
physical and emotional well-being, role functioning, satis-
faction with the partner and family relationship, as well as
sexual function and satisfaction. There are two important
effects of progesterone on the combined physical, mental and
sexual well-being of the climacteric patient. The first is the
antiestrogenic effect of progesterone on the peripheral phys-
ical level which not only protects the endometrium against
overstimulation but also reduces individual suffering from
heavy bleeding, breast tension, bloating and general discom-
fort. The second effect is due to the complex action of pro-
gesterone in the brain. Studies using different progestins in
different dosages and in different regimens show contradic-
tory results. Some studies demonstrate an increase in depress-
ed mood and reduced well-being while using synthetic
progestins. Other studies, however, indicate an anxiolytic and
sometimes antidepressant effect of progesterone and proges-
terone-like progestins with an improvement of emotional
well-being and quality of life. In the individual patient, the
positive or negative emotional and mental state can be con-
ditioned by various pathways of progesterone and progestins.
The antiestrogenic effect can attenuate the psychotropic
effect of estradiol (E2) on the brain, thus reducing emotional
well-being. Progesterone interacting with many brain areas
can have a mood stabilizing and anxiolytic effect through the
action on the GABA receptor. This effect seems to be strong-
est when using natural progesterone and the effect varies
considerably among different progestins and different dos-
ages due to metabolic pathways involving the production of
allopregnanolone or other metabolites. In conclusion, the
positive anxiolytic and sedative effects of progesterone on
the central nervous system depend on the type of progesto-
gen, the dosage, the timing of application, the combination
with estrogen, etc. Progesterone and progestins have impor-
tant potential to maintain or improve the psychosomatic
health of women. Their use must, however, be tailored to
specific symptom clusters and to the individual’s pre-existing
psychosomatic health status.
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Introduction
Psychosomatics as a medical perspective and discipline
focuses on the interaction of physical and mental health in
a specific life situation of a patient, taking into account the
physical and emotional well-being, role functioning, satis-
faction with the partner and family relationship, as well as
sexual function and satisfaction. It is therefore close to the
concept of quality of life but it is less focused on separate
aspects but more on the interaction between the different
health parameters (1).
We attempted to evaluate the importance of progesterone
and progestins on different components of the quality of life
of women including somatic and mental health as well as
well-being and role functioning.
Progesterone has many functions in the female body,
including: as a precursor of estrogen and testosterone, it
gives protection to the endometrium, its reproductive capac-
ity, its neuronal integrity, it is a natural diuretic, it helps use
fat for energy, helps thyroid hormone action, helps normalize
blood sugar levels, normalizes zinc and copper levels, and
restores proper cell oxygen levels.
These actions contribute to the positive role of progester-
one in reproductive health, bone health, cardiovascular health
and neurological health. Apart from these protective and
health-maintaining effects, progesterone alleviates estrogen-
induced symptoms such as heavy bleeding, breast tension,
nervousness, sleep disturbances, etc.
The action of progesterone on the brain, however, is mani-
fold and complicated, which is indicated by the large number
of brain regions that have progesterone receptors and by the
fact that progesterone exerts genomic and non-genomic
actions (2).
In clinical practice, we have to distinguish between the
use of natural progesterone and synthetic progestins. Both
have typical clinical indications which they share, such as in
endometriosis, disorders of the endometrium and endometri-
um protection. Natural progesterone finds its use in assisted
reproductive techniques (ART) and prevention of threatened
abortion and could have future use in cardiovascular
prevention.
Synthetic progestins are used in contraception. In com-
bined hormonal contraceptives, they have a protective effect
on the endometrium and ovarian cancer. Synthetic progestins
have known risks regarding cardiovascular disease and breast
cancer. These risks depend, however, on the molecular struc-
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ture of the progestin and whether they are used in combi-
nation with synthetic estrogens (3).
Is progesterone good or bad for the global
well-being of the woman?
The results of clinical studies are controversial and show the
complexity of the progesterone action. Some studies point to
a more negative effect of progestins on mental well-being
and mood.
Hammarba¨ck et al. (4) studied the effect of exogenously
administered sequential estrogen/progestin postmenopausal
replacement therapy on mood and physical signs. They
included 22 women requiring postmenopausal estrogen and
divided the women into two groups. The first group of 11
women were given estradiol treatment only (oestrogel cream,
3 mg percutaneously/day) for 21 days with a subsequent
break of 7 days. The other 11 women were given in addition
a synthetic progestin (lynestrenol, 5 mg/day) during the last
11 days of treatment.
The group with estrogen treatment only did not show any
cyclical worsening in mood or physical signs during the
treatment. The women who in the latter stage of the estrogen
treatment cycle also received progestogen showed significant
cyclicity in both moods and physical signs, with a maximum
symptom degree during the final days of gestagen treatment.
The negative mood change started 1–3 days after progesto-
gen was added to the treatment. The authors concluded that
these results suggest that progestins are involved in causing
cyclical symptom changes seen in the premenstrual syn-
drome (PMS).
In a further publication, Ba¨ckstro¨m et al. (5) concluded
that in ‘‘hysterectomized women only estrogen replacement
is strictly necessary. Indeed, there is no imperious need for
administrating progesterone/synthetic progestins other than
for preventing the risk of endometrial hyperplasia and/or
cancer’’. Characteristically, hysterectomized women show
better and longer compliance to treatment than women with-
out hysterectomy. This should be taken as a strong indicator
that it is the side effects generated by progestins which
together with bleeding hamper long-term hormone replace-
ment therapy compliance.
Magos et al. (6) investigated possible negative effects of
progestogens on mood. This was a prospective placebo-con-
trolled study investigating the influence of norethisterone on
mood and behavior. A total of 58 postmenopausal hysterec-
tomized women were treated with subcutaneous estradiol and
testosterone implants. Norethisterone, 2.5 or 5 mg daily, was
given for 7 days and a placebo for two periods of 7 days.
There were widespread adverse effects which were dose-
related. Significant changes in five of the eight symptom
complexes studied (pain, concentration, behavioral change,
water retention and negative affect) were found with 5 mg/day
of norethisterone acetate. The symptoms were similar to the
typical complaints of PMS, such that a combination of estra-
diol and testosterone implants with cyclical oral nor-
ethisterone appeared to be a model for this condition. The
authors concluded that the dose of this progestogen should
therefore be the minimum to achieve the desired therapeutic
effect.
Other studies came to different conclusions showing more
positive effects of other progestins on mood such as anxio-
lytic and even antidepressant action. Siddle et al. (7) studied
16 postmenopausal women who received conjugated equine
estrogens, 1.25 mg/day, continuously. They were randomly
allocated to add dydrogesterone, 20 mg/day, for 12 days each
calendar month for 3 months and then 10 mg/day in an iden-
tical manner for a further 3 months, or to receive the dydro-
gesterone doses in reverse sequence. Anxiety and physical
and psychological status were significantly improved after 3
months of therapy. Significant benefits on depression were
less clearly observed. There were no differences between the
two dydrogesterone doses on anxiety, depression and phys-
ical and psychological status and, overall, the addition of the
progestogen did not antagonize estrogen benefits.
Cagnacci et al. (8) published a randomized, placebo-con-
trolled study of 120 postmenopausal women on continuous
hormone replacement therapy with transdermal estradiol (50
mg/day) who were receiving for 10 out of every 28 days
four different progestins: dydrogesterone (DYD; 10 mg/day;
ns20), medroxyprogesterone acetate (MPA; 10 mg/day;
ns20), nomegestrol acetate (NMG; 5 mg/day; ns20), or
norethisterone acetate (NETA; 10 mg/day; ns20).
Anxiety, by the state-trait anxiety inventory, and depres-
sion, by the self-evaluation depression scale of Zung, were
evaluated just prior to and in the last 2 days of the 10-day
progestins adjunct.
Anxiety was decreased by DYD (–2.3q1.1; p-0.01) and
MPA (–1.5q0.5; p-0.01), but not by NMG or NETA.
Depression did not significantly increase during progestins
and actually decreased during MPA (–3.0q0.7; p-0.01).
Only the effect of DYD on anxiety and that of MPA on
depression were significant compared to the control group
(p-0.05).
From these studies, it became clear that effects on well-
being and mood are not only dose-dependent but also depend
on the type of progestin used. Progestins with a structure
very close to natural progesterone seem to have a desirable
anxiolytic and sedative effect, whereas synthetic progestins
derived from androgens can lead to depressive mood states,
possibly through their pronounced antiestrogenic action.
Other studies indicate that the effect also depends on
pre-existing clinical conditions of the women using
progestogens.
Andreen et al. (9) investigated the effect on mood and
physical symptoms of two dosages of natural progesterone
and a placebo in postmenopausal women with and without
a history of PMS.
They included 36 postmenopausal women with climacteric
symptoms. The women received 2 mg estradiol continuously
during three 28-day cycles. Vaginal progesterone supposito-
ries of 800 mg/day, 400 mg/day, or placebo were added
sequentially for 14 days per cycle. The following results
were found. Women without a history of PMS showed cycli-
city in both negative mood and physical symptoms while on
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400 mg/day progesterone but not on the higher dose or the
placebo. Women without a history of PMS had more physical
symptoms on progesterone treatment compared with placebo.
Women with prior PMS reported no progesterone-induced
symptom cyclicity. The authors concluded that the addition
of progesterone in postmenopausal women can have an
opposite effect on cyclic physical and emotional symptoms
depending on the pre-existing vulnerability of estrogen/pro-
gesterone exposition and that there was a dose-related effect.
Another area to study effects of progestogens on mood is
in women who take oral contraceptives (OC). Joffe et al.
(10) performed a nested case-control study within a com-
munity-based cohort of 976 premenopausal women in the
US. They showed that of 658 women on OC, 16.3% of the
women reported OC pill-related premenstrual mood deteri-
oration, 12.3% of the women reported premenstrual mood
improvement. In adjusted models, previous depression was
the only significant predictor of mood deterioration wodds
ratio (OR) 2.0; 95% confidence interval (CI) 1.1–3.8x; early-
onset premenstrual mood disturbance and dysmenorrhea
were significant predictors of OC pill-related mood improve-
ment (OR 3.1; 95% CI 1.9–5.2 and OR 2.3; 95% CI 1.4–3.9,
respectively).
The authors concluded that OC pills do not influence pre-
menstrual mood in most women. Premenstrual mood is most
likely to deteriorate in women with a history of depression
and to improve in women with early-onset premenstrual
mood disturbance or dysmenorrhea.
Similar results were published by Oinonen and Mazma-
nian (11). In their meta-analysis, they found that compared
with non-users, OC users experience less variability in effect
across the entire menstrual cycle and less negative effect dur-
ing menstruation (i.e., withdrawal bleeding). They examined
in women with OC-related negative mood and effect change
as to whether there were potential mediators of the relation-
ship between OCs and mood or effect, and they identified
the following mediators: history of depression, psychiatric
symptoms, dysmenorrhea, and premenstrual mood symptoms
prior to OC use; a history of pregnancy-related mood symp-
toms; a family history of OC-related mood complaints; being
in the postpartum period; and age.
Furthermore, a lower ratio of progesterone to estrogen was
associated with more negative mood change in women with
a history of premenstrual emotional symptoms, higher pro-
gesterone to estrogen ratios are associated with increased
negative mood effects in women without such a history, and
monophasic OCs have a greater stabilizing effect on mood
than triphasic OCs.
There seems to be a group of women, especially those
with pre-existing PMS, premenstrual dysphoric disorder
(PMDD) or affective disorder, who suffer either from the
fluctuation of progesterone or/and from the shift of the estro-
gen/progesterone ratio to an estrogen dominant state. These
women benefit from prescription of progesterone or a natural
progestogen for their psychosomatic health.
Rapkin et al. (12) studied healthy OC pill-naive women
without current or history of affective disorder. These women
received 0.020 mg ethinyl estradiol (E2)-combined with 0.1
mg levonorgestrel as OC for 3 months. They measured serum
neuroactive steroids allopregnanolone, allotetrahydrodeoxy-
corticosterone, and dehydroepiandrosterone (DHEA); neu-
roactive steroid precursors P and pregnenolone; E2. Mood
and anxiety were assessed by the Premenstrual Syndrome
Daily Ratings Form, Beck Depression Inventory, Spielberger
State-Trait Anxiety Inventory, and Profile of Mood States.
The combined OC pill resulted in a decrease in neuroac-
tive steroids and neuroactive steroid precursors as well as in
E2. However, this decline was not associated with adverse
mood changes on any of the well-validated assessment tools.
Healthy women without underlying mood or anxiety dis-
order who were given a low-dose OC pill did not experience
adverse psychological symptoms despite a significant reduc-
tion in neuroactive steroids.
How to explain controversial empirical results?
There are several possible explanations for the complex and
sometimes unpredictable action of progesterone or proges-
terone derivatives in these women (4, 7, 8).
The differential action of progesterone metabolites
on the GABA receptor
GABA receptor activation through chloride channels open-
ing is induced by allopregnanolone, epipregnanolone, andro-
stenedione and androsterone, thus producing a sedative and
anxiolytic effect. Other metabolites such as dehydroepian-
drosteronesulfate (DHEAS), pregnenolone, pregnenolone
sulfate and corticosterone have an opposite chloride channel
closing effect on the GABA receptor, thus producing an
arousal state. Clinical examples of symptoms and disorders
caused by the differential action of GABA steroids are seda-
tion, memory and learning disturbance, clumsiness, increased
appetite, worsening of petit mal epilepsy, negative mood
such as tension, irritability and depression during hormone
treatment, and PMDD. A malfunctioning GABA-A receptor
system or genetically determined metabolic pathways lead-
ing to a disbalance of metabolites can thus be related to stress
sensitivity, concentration difficulties, loss of impulse control,
irritability, anxiety and depression. A well-functioning
GABA system and well-balanced metabolism, by contrast,
can exert positive mood stabilizing, anxiolytic and sedative
actions.
The effect of dosage
Animal and human studies show that GABA-A receptor-pos-
itive modulators such as barbiturates, benzodiazepines, alco-
hol and allopregnanolone have a bimodal effect. In pharma-
cological concentrations, they are central nervous system
depressants, anesthetic, antiepileptic and anxiolytic. In low
dosages and concentrations, reached endogenously, they
can induce adverse emotional reactions in up to 20% of
individuals.
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The effect of GABA steroids
GABA steroids can also induce tolerance to themselves and
similar substances, and rebound occurs at withdrawal. A con-
tinuous exposure to GABA steroids causes tolerance, and
women with PMDD are less sensitive to GABA-A modula-
tors. An example of withdrawal effect is ‘‘catamenial epi-
lepsy’’, when seizures increase during menstruation after the
withdrawal of GABA steroids.
There is a direct link between stress and GABA steroids.
The adrenals produce specific GABA steroids under stress
and this production is individually different. The variable
antiestrogenic effect of various progestins can lead to dep-
ressive symptoms and diminution of emotional well-being
(13, 14).
Consequences and conclusions from a
psychosomatic perspective
Progesterone plays a very basic multifunctional role in the
female body including the brain, with effects modulated by
time of exposure, dosage, metabolism, tolerance, withdrawal,
etc. The common denominator of the action is balancing and
stabilizing the endocrine, physical and emotional milieu. Pro-
gesterone is linked to the stress reaction and is thus part of
the stress response system. At present, the clinical task con-
sists of enhancing the balancing, stabilizing and protective
actions of progesterone and progestogens by individualizing
treatment:
• Look for physical and emotional symptoms indicative of
progesterone deficiency.
• Choose a progestogen as natural as possible with an indi-
vidualized dosage.
• Continuously adapt the dosage according to the
symptoms.
• If necessary (in the case of complex symptomatology and
insufficient response) integrate treatment into a disorder
specific therapy including cognitive behavioral therapy
and eventually psychopharmacological treatment.
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